Novacyt has launched an upgraded version of its DPYD pharmacogenomics assay on schedule, which should help future growth prospects as the product receives regulatory approvals over the next few months. The upgraded assay incorporates features to comply with the latest clinical guidelines and should restore Novacyt’s competitive advantage in the field. It is a high margin product with strong international growth potential. We make no change to forecasts at this stage, but view this as another positive as the business continues its move towards sustainable profitability.